Kayser O, Olbrich C, Yardley V, Kiderlen AF, Croft SL (2003): Formulation of amphotericin B as nanosuspension for oral administration
Int. J. Pharm. 254: 73-75.

Amphotherin B was formulated in a nanosuspension as a new oral drug delivery system for the treatment of experimental visceral leishmaniasis. Amphotericin B (AmB) nanosupensions were produced by high pressure homogenisation obtaining particles with a PCS diameter of 528 nm. Environmental stability was determined in artificial gastrointestinal fluids at different pH and electrolyte concentrations. In vivo efficacy was determined in a mouse model of visceral leishmaniasis. Following oral administration (5 mg kg^-1), micronised AmB B did not show any curative effect. However, administrations of AmB nanosuspension, reduced liver parasite load by 28.6% compared to untreated controls.